Efficacy and safety of abacavir/lamivudine plus rilpivirine as a first-line regimen in treatment-naïve HIV-1 infected adults

Sharlene Ho1, Joshua Guoxian Wong2, Oon Tek Ng3,4,5, Cheng Chuan Lee3,4,6, Yee Sin Leo3,4,5,6,7, David Chien Boon Lye3,4,5,6 and Chen Seong Wong3,4,6*

Abstract

Background: The anti-retroviral combination of abacavir/lamivudine plus rilpivirine (ABC/3TC/RPV) is not recommended by international guidelines as the first-line regimen. However, it is potent, well-tolerated, and affordable, especially in resource-limited settings. This study evaluates the efficacy and safety of ABC/3TC/RPV as an initial regimen for treatment-naïve HIV-1 infected patients.

Methods: A retrospective study was conducted in the largest HIV care centre in Singapore, with data collected June 2011 to September 2017. All treatment-naïve HIV-1 infected adults prescribed ABC/3TC as part of their initial antiretroviral therapy regimen were included. The third drug was a non-nucleoside reverse-transcriptase inhibitor (NNRTI) such as RPV or efavirenz (EFV), or boosted protease-inhibitor (PI). Patients were followed up for 48 weeks. The primary end-point was the percentage of patients achieving virologic suppression, analysed using on-treatment analysis. Secondary outcomes included CD4-count change, treatment discontinuation and treatment-related adverse events.

Results: 170 patients were included in the study, 66 patients in the RPV group, 104 patients in the comparator group (EFV or boosted PI). 96% (n = 24) in the RPV group and 87% (n = 26) in the comparator group achieved viral suppression at 48 weeks (p = 0.28). Median (interquartile range) time to viral suppression was similar: 17 (14–24) weeks in the RPV group, and 21 (13–26) weeks in the comparator group. There were no statistically significant differences in the CD4 count between the two groups. 14% (n = 9) of patients on RPV discontinued treatment before 48 weeks, compared to 30% (n = 31) from the comparator group (p = 0.053). Of these, 23 discontinuations were due to drug adverse effects, and only 1 attributed to RPV (p < 0.01). One patient in each group had virologic failure.

Conclusion: RPV is effective, safe and considerably more tolerable than compared to NNRTI or boosted PI in ABC/3TC-containing regimens for treatment-naïve patients. It offers an affordable and attractive option, especially in resource-limited settings.

Keywords: Abacavir, Rilpivirine, Antiretroviral, Treatment-naïve, HIV

Background

Current combination anti-retroviral therapies (cART) against human immunodeficiency virus (HIV) are highly effective. Conventional three-drug cART regimens for treatment naive patients generally consist of two nucleoside reverse transcriptase inhibitors (NRTIs) and a third drug from another class: integrase strand transfer inhibitors (INSTI), non-nucleoside reverse transcriptase inhibitors (NNRTI) or protease inhibitors (PI). In 2019, the World Health Organisation (WHO) updated its recommendations on the preferred first-line HIV regimen-favouring INSTIs in combination with two NRTIs [1].
Similar recommendations have also been put forth by the United States Department of Health and Human Services (DHHS) and European AIDS Clinical Society (EACS) guidelines [2, 3]. These changes have largely been driven by increasing concerns of the rising HIV drug resistance to NNRTIs, especially in Africa [4]. In Asia, the prevalence of pre-treatment NNRTI resistance is considerably lower, with the yearly increase in the odds of pre-treatment drug resistance reported as 11% (2–20%) [4]. The use of NNRTIs is still recommended as an alternative first-line regimen and in certain settings [1–3]. Besides drug resistance, many factors have to be considered when selecting a cART regimen, such as virologic efficacy, adverse effect profile, comorbid conditions, drug interactions, pill burden, cost and access [2, 3].

NRTI backbone therapies include tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide (TAF) (a prodrug formation of TDF) in combination with emtricitabine (FTC) or lamivudine (3TC), and abacavir and lamivudine (ABC/3TC). ABC/3TC offers the main advantage of avoiding potential renal and bone toxicity seen with tenofovir based regimen and can be used in individuals with renal insufficiency and osteoporosis [5, 6]. It is also safe to be used in the paediatric population [1].

Rilpivirine (RPV) is a second-generation NNRTI approved for use with NRTIs in treatment-naive HIV-1 patients with pre-treatment viral loads of less than 100,000 copies/ml [2, 3]. Its use is recommended to be limited to patients with pre-treatment CD4 counts exceeding 200 cells/mm³ [2, 3]. RPV has fewer reported neurologic and psychiatric adverse effects compared with efavirenz (EFV) [7], and a more favourable metabolic profile compared with protease inhibitors, making it an attractive third drug in combination with NRTIs [8]. The combination of ABC/3TC plus RPV is a once-daily regimen with low pill burden [7]. This combination is also among the most cost-effective regimens because it is relatively inexpensive; and does not require regular monitoring of renal function, urinalysis and bone mineral density as with the use of tenofovir-containing regimens. This is particularly important in settings with limited healthcare resources.

However, data on the use of ABC/3TC in combination with RPV in treatment-naive patients are scarce. Most patients in the ECHO and THRIVE clinical trials received TDF/FTC as the NRTI backbone, and only 35 patients in the THRIVE study received ABC/3TC plus RPV [9–11]. Current guidelines do not recommend it as an initial regimen for treatment-naive patients [1–3]. However, in 2016, Curran et al. have reported the effectiveness and safety of ABC/3TC plus RPV in 84 treatment-naive HIV-1 patients in a retrospective cohort study in Spain [12].

The purpose of this study is to evaluate the efficacy and safety of ABC/3TC plus RPV as an initial regimen for treatment-naive HIV-1 patients in routine clinical practice in Singapore.

**Methods**

**Study design and patients**

This was a retrospective study conducted at the National Centre for Infectious Diseases (NCID), which provides HIV care for the largest cohort of HIV-infected individuals in Singapore, between June 2011 and September 2017. All treatment-naive HIV-1 infected patients (≥18 years old) who received ABC/3TC were included. The third drug could either be a NNRTI (RPV or EFV) or boosted PI (atazanavir or darunavir). Exclusion criteria were pre-treatment viral load > 100,000 copies/ml, CD4 count < 200 cells/mm³, hepatitis B co-infection (requiring treatment with TDF) and pregnancy.

Data were collected from the NCID HIV Clinical Database, a standardised computerised database containing records of demographic information, HIV transmission route, baseline viral load and CD4 count, AIDS-defining illnesses, cART regimen history and treatment-associated adverse events. Individual patient case records were reviewed to determine underlying medical conditions and to obtain laboratory results such as lipid profile, kidney and liver function tests when these were not available on the Clinical Database. Patients were followed up for 48 weeks from initiation of cART. The interval for follow-up was determined by individual attending physicians as per routine clinical care guidelines. During follow-up, information regarding viral load, CD4 count, laboratory parameters, treatment-related adverse events, and reasons for discontinuing cART, if any, were collected. If cART was stopped due to virologic failure, genotype resistance testing (GRT) was done. Data were anonymised upon extraction. The follow-up was censored for analyses in March 2018.

Virologic response was classified according to the definitions in the DHHS guidelines [2]. Virologic suppression was defined as viral load < 40 copies/ml, based on the lower limit of detection of the laboratory assay used by our institutional laboratory, which determined HIV-RNA levels using the Abbott Realtime HIV-1 assay. Virologic failure was defined as the inability to achieve or maintain viral load < 200 copies/ml. After achieving virologic suppression, a confirmed viral load > 200 copies/ml was considered virologic rebound, whereas an isolated detected HIV-RNA level = 40 copies/ml but < 200 copies/ml that was followed by a return to virologic suppression was considered virologic blip.

The primary efficacy end-point was the percentage of patients who achieved virologic suppression (viral
load < 40 copies/ml). This outcome was analysed using on-treatment analysis, in which discontinuation and missing data were censored. The median time taken to achieve virologic suppression was also analysed. Secondary outcomes were changes in CD4 count, treatment discontinuation, treatment-related adverse events, and lipid, kidney and liver profile changes.

Statistical analysis

Univariate analyses were carried out using the Chi square and Fisher’s exact test for categorical variables. Kaplan–Meier survival curves were drawn to show median time to HIV viral load suppression, for the 2 treatment regimes. Log-rank tests were used to test for differences between the 2 survival functions. Cox proportional hazards model was used to obtain the treatment effect sizes. When necessary, follow-up was categorised into 12-weekly intervals. Using Stata MP 13 (Stata Corp, Texas, USA), all analyses were performed at a 5% significance level.

Results

A total of 216 patients were screened, based on the inclusion criteria of being prescribed ABC/3TC as first-line cART. Of these, 170 patients were included in the study after excluding those with incomplete data (n = 8), pre-treatment viral load > 100,000 copies/ml (n = 19) and CD4 count < 200 cells/mm³ (n = 19). Sixty-six patients (39%) received ABC/3TC plus RPV and 104 patients (61%) received ABC/3TC plus EFV or a boosted PI (Table 1, Fig. 1, Additional file 1). Of the 104 patients, 89 received EFV, 3 received ritonavir-boosted darunavir and 12 received ritonavir-boosted atazanavir.

There were no significant differences in the baseline characteristics between the RPV group and the EFV or boosted PI group (Table 1). Median (Interquartile range, IQR) age at HIV diagnosis was 35 (28–46) years old in the RPV group and 39 (30–49) years old in the EFV or boosted PI group. The majority of patients were males (n = 158, 93%) and Chinese (n = 118, 69%), reflecting the general epidemiology of HIV infection in Singapore. The most common route of HIV transmission was via homosexual transmission (n = 96, 56%). None had AIDS defining illness at diagnosis. Five patients (3%) had HCV co-infection. The median (IQR) time from diagnosis to treatment was 67 (45–215) days for the RPV group, and 84 (48–351) days for the EFV or boosted PI group. No differences in baseline HIV viral load or CD4 count were observed between the groups. Seventy-five percent (n = 127) had Human Leukocyte Antigen (HLA) B*5701 testing, and 49% (n = 84) had HIV GRT done prior to starting treatment. The most common co-morbidities

| Table 1 Baseline characteristics of patients |
|---------------------------------------------|
| ABC/3TC/RPV (n = 66) (%) | ABC/3TC/EFV or boosted PIs (n = 104) (%) | p-value |
| Age, years, median (IQR) | 35 (28–46) | 30 (30–49) | 0.04 |
| Male | 63 (95.4) | 95 (91.3) | 0.37 |
| Race | | | 0.40 |
| Chinese | 45 (68.2) | 73 (70.2) | |
| Malay | 16 (24.2) | 21 (20.2) | |
| Indian | 5 (7.5) | 5 (4.8) | |
| Others | 0 (0) | 5 (4.8) | |
| HIV transmission route | | | 0.20 |
| Homosexual | 42 (63.6) | 54 (52) | |
| Heterosexual | 12 (18.2) | 30 (28.9) | |
| Bisexual | 8 (12.1) | 18 (17.3) | |
| IVDU + sexual contact | 2 (3.0) | 1 (1.1) | |
| Others | 2 (3.0) | 1 (1) | |
| Baseline viral load (copies/ml) | | | 0.42 |
| < 10,000 | 21 (31.8) | 24 (23.1) | |
| 10,000–50,000 | 34 (51.5) | 58 (55.8) | |
| > 50,000 | 11 (16.7) | 22 (21.2) | |
| Baseline CD4 count | | | 0.37 |
| 200–350 | 21 (31.8) | 44 (42.3) | |
| > 350–500 | 21 (31.8) | 30 (28.8) | |
| > 500 | 24 (36.4) | 30 (28.8) | |
| AIDS defining illness | 0 (0) | 0 (0) | NA |
| HCV co-infection | 2 (3.0) | 3 (2.9) | 0.95 |
| Genotype test at diagnosis | 29 (44.0) | 55 (52.9) | 0.26 |
| Time from diagnosis to treatment, days, median (IQR) | 67 (45–215) | 84 (48–351) | 0.27 |
| HLA B*5701 | | | <0.01 |
| Positive | 0 (0) | 1 (1.0) | |
| Negative | 61 (92.4) | 65 (62.5) | |
| Not done | 5 (7.6) | 38 (36.5) | |
| Comorbidities | | | |
| Diabetes mellitus | 5 (7.5) | 6 (5.8) | 0.64 |
| Hypertension | 7 (10.6) | 9 (8.6) | 0.67 |
| Hyperlipidemia | 5 (7.6) | 9 (8.7) | 0.80 |
| IHD/CAD | 1 (1.5) | 2 (1.9) | 0.84 |
| Congestive cardiac failure | 0 (0) | 0 (0) | NA |
| Chronic liver disease | 0 (0) | 0 (0) | NA |
| Chronic kidney disease | 0 (0) | 3 (2.9) | 0.16 |
| Cancer | 0 (0) | 1 (1) | 0.42 |
| CVA | 0 (0) | 0 (0) | NA |
| Osteoporosis | 0 (0) | 0 (0) | NA |

ABC abacavir, 3TC lamivudine, RPV rilpivirine, IQR interquartile range, IVDU intravenous drug use, AIDS acquired immunodeficiency syndrome, HCV hepatitis C Virus, IHD ischaemic heart disease, CAD coronary artery disease, CVA cerebrovascular accident
were hypertension (n = 16, 9%), hyperlipidaemia (n = 14, 8%) and diabetes mellitus (n = 11, 6%).

In the on-treatment analysis, the percentage of patients who achieved virologic suppression at 48 weeks was similar between the two groups. It was 96% (n = 24) in the RPV group and 87% (n = 26) in the EFV or boosted PI group, p = 0.28 (Fig. 2). The median time taken to achieve virologic suppression was also similar (Fig. 3). In the RPV group, median (IQR) time to viral load < 40 copies/ml was 17 (14–24) weeks. In the EFV or boosted PI group, it was 21 (13–26) weeks. There were no statistically significant differences in the CD4 count between the two groups. In the RPV group, the median (IQR) CD4 count changed from 457 (346–604) cells/mm³ to 583 (513–660) cells/mm³ and in the EFV or boosted PI group, from 394 (297–511) cells/mm³ to 574 (479–665) cells/mm³ over the 48-week period (Fig. 4).

Nine out of 66 patients (14%) from the RPV group had discontinuation of treatment before 48 weeks, compared with 31 out of 104 patients (30%) from the EFV or boosted PI group (p = 0.05). In the RPV group, 1 patient discontinued treatment due to an adverse reaction, 1 had virologic failure, 3 defaulted clinic follow-up and 4 had other reasons for discontinuation. In the EFV or boosted PI group, the main reason for discontinuation was adverse reactions (n = 22, 71%). One patient had virologic failure, 4 defaulted clinic follow-up, 1 had cART regimen switched based on a decision made by the attending physician, 1 patient requested for cART switch, 1 patient died and 1 had other reasons for discontinuation (Fig. 1). The patient who died was a 53-year-old man with lung cancer, and had received ABC/3TC plus EFV for 36 weeks with virologic suppression before his death.

A total of 23 patients discontinued their initial cART due to adverse reactions (Table 2). Twenty-one had received EFV, 1 had received ritonavir-boosted atazanavir and 1 had received RPV (p < 0.01). The most common adverse reactions were neuropsychiatric side effects (n = 13, 46%) and rash (n = 12, 43%). Most of the adverse reactions were mild and only 3 required treatment or hospitalisation. One patient on ABC/3TC plus EFV tested positive for HLA B*5701. Abacavir was immediately discontinued and switched to tenofovir based regimen when the HLA B*5701 results were available after 1 week on abacavir. He did not experience the abacavir hypersensitivity reaction.

Two patients fulfilled the DHHS guideline criteria for virologic failure. One patient who received ABC/3TC plus RPV had a viral load of 9730 copies/ml at 24 weeks and 26,200 copies/ml at 32 weeks. GRT showed multiple NRTI, NNRTI and PI associated mutations. These included M41L, D67N, M184V, T215Y, K101KE, E138EAG, Y181C, Y188YFHL, and M230ML mutations, many which are associated with high levels of reduced
Fig. 2 On-treatment viral suppression. RPV rilpivirine, EFV efavirenz, PI protease inhibitor

| Group               | Baseline | < 12 weeks | 12-24 weeks | 25-36 weeks | 37-48 weeks |
|---------------------|----------|------------|-------------|-------------|-------------|
| RPV                 | 0% (0/57)| 75.0% (3/4)| 75.0% (30/40)| 100.0% (24/24)| 96.0% (24/25) |
| EFV or boosted PI   | 0% (0/73)| 12.5% (1/8)| 69.4% (25/36)| 87.9% (29/33)| 86.7% (26/30) |

Fig. 3 Time taken to achieve virologic suppression. RPV rilpivirine, EFV efavirenz, PI protease inhibitor, ART anti-retroviral therapy, VL40 viral load < 40 copies/ml
susceptibility to ABC/3TC as well as RPV [13]. He did not have GRT done prior to starting cART. This patient was switched to TDF/FTC plus dolutegravir. Another patient on ABC/3TC plus boosted atazanavir had a viral load of 180 copies/ml at 8 weeks and 133,400 copies/ml at 20 weeks. He was found to be non-adherent to ART because of gastrointestinal side effects, and was later switched to zidovudine/lamivudine plus ritonavir-boosted atazanavir. GRT for this patient revealed pan-susceptible wild-type virus.

Three patients had virologic rebound: 2 from the EFV or boosted PI group and 1 from the RPV group. The first patient had a viral load of 35,136 copies/ml at 48 weeks after achieving virologic suppression previously. He was non-adherent to EFV because of giddiness and drowsiness, and EFV was switched to ritonavir-boosted lopinavir, achieving undetectable viral load thereafter. His GRT showed K103N, reflecting a reduced 20-fold reduced susceptibility to EFV [13]. His GRT done prior to starting cART showed pan-susceptible wild-type virus.

The second patient, also in the EFV group had a viral load of 493 copies/ml at 20 weeks despite previously achieving virologic suppression. His viral load subsequently became suppressed at < 40 copies/ml at 28 weeks without changing cART regimen. The third patient on RPV had a viral load of 220 copies/ml at 36 weeks, which came down to < 40 copies/ml at 52 weeks without changing cART. The second and third patients did not have GRT done.

There were no significant changes in the lipid, kidney and liver profiles at 48 weeks between the two groups (Fig. 5).

### Discussion

Data on ABC/3TC plus RPV as initial regimen in treatment-naïve HIV-1 infected patients are scarce. In the THRIVE study, only 35 patients received ABC/3TC plus RPV, with an overall efficacy of 86%, without apparent differences between different NRTI backbones [10]. In 2016, Curran et al. reported the use of this combination in 84 patients, with effectiveness at 12 months of 97% (on-treatment analysis) and 86% (intention-to-treat analysis). They reported 2 virologic failures and 7 treatment
discontinuations (of which one case was due to treatment-related adverse reaction) [12]. Our study showed that ABC/3TC plus RPV can serve as an effective alternative initial regimen for treatment-naïve HIV-1-infected patients with pre-treatment viral loads <100,000 copies/ml and CD4 count > 200 cells/mm³. We report treatment efficacy of 96% at 12 months, which is similar to previous studies in the published literature. In addition, there was no significant difference in the virologic effectiveness compared with the EFV or boosted PI group.

Our study also showed that ABC/3TC plus RPV is a safe and tolerable regimen with fewer adverse reactions and subsequent treatment discontinuations compared with ABC/3TC plus EFV or boosted PI. Most discontinuations were seen in patients receiving ABC/3TC plus EFV. The main reason was neuropsychiatric side effects from EFV such as abnormal dreams, insomnia, headache, giddiness and depression, which are well-described and have prompted the EFV-based cART regimens to be recommended as alternative regimens by the DHHS and other guidelines [2, 14]. RPV, a second generation NNRTI, has fewer neuropsychiatric side effects and is better tolerated, as seen in our study, and evidenced by the fewer discontinuations due to intolerance. This is reflected also in the ECHO, THRIVE and STaR trials utilising the TDF/FTC backbone [9–11, 15]. Although RPV has a better metabolic profile compared with PI, this was not reflected in our study, mainly because there were very few patients on ABC/3TC plus boosted PI, precluding significant differences in metabolic complications to be detected. Kidney and liver function remained stable at 48 weeks, further underlining the safety of ABC/3TC plus RPV.

A significant advantage of using ABC/3TC plus RPV is its once-daily dosing frequency, proffering a regimen with low pill burden and small pill size. It consists of two tablets taken daily, with RPV being one of the smallest ART tablet available at 6.4 mm in diameter [16]. Moreover, the cost of RPV is comparable with that of EFV, and much less than that of PIs in Singapore and many other resource-limited settings. Given that RPV performs similarly to these comparators in terms of efficacy, this lower cost argues for the cost-effectiveness of RPV-containing cART regimens. This has been shown by other investigators in other settings [17]. The combination of simplicity, convenience and affordability of this cART regimen

![Fig. 5 Changes in lipid, kidney and liver profiles at 48 weeks. RPV rilpivirine, EFV efavirenz, PI protease inhibitor, LDL low density lipoprotein, HDL high density lipoprotein, ALT alanine aminotransferase](image)
makes it an attractive option for first-line therapy in treatment-naïve patients, especially in settings where cost is an important consideration, such as when co-payment for treatment is required, as is the case in Singapore. These patient-centric factors also increase the likelihood of sustained adherence to the regimen.

Important considerations when using RPV include that it needs to be taken with meals to ensure adequate bioavailability and to avoid co-administration with drugs that reduce gastric acidity such as proton pump inhibitors as RPV absorption is dependent on gastric pH [7, 16]. There is also the potential interaction with drugs that undergo cytochrome P450-mediated metabolism [7, 16]. These issues were not seen in our patients and none required discontinuations because of the above reasons. However, these concerns remain important, especially as comorbidities and polypharmacy become more prevalent in an ageing population of HIV-infected individuals.

Our study has several limitations. It was a retrospective, single centre study with relatively small sample size, and there may have been systematic differences in the two groups that could have served as confounders for the observed differences in outcome. We note a predominance of males in our study population, which reflects the general HIV epidemiology in Singapore, however it may not be representative of other populations. Furthermore, not all patients had the same duration of follow-up or interval between follow-up visits. This reflects variation in clinical practice among clinicians. Despite this, the median time to virologic suppression was approximately 17 weeks for the RPV group and 21 weeks for the EFV or boosted PI group. Longer follow-up of these patients would allow better evaluation of the long-term effectiveness and safety of this regimen. It is also imperative to note the limitations of this regimen: reduced efficacy in patients with high pre-treatment viral load and low CD4 count; the lack of safety data in pregnancy; and potential interactions with commonly used medications such as rifampicin and proton-pump inhibitors.

In conclusion, we present the first analysis that directly compared ABC/3TC plus RPV versus ABC/3TC plus EFV or boosted PI as a first-line regimen in treatment-naïve HIV-1 patients. We found similar efficacy and safety of RPV in combination with ABC/3TC in the clinical setting (Additional file 1).

**Supplementary information**

Supplementary information accompanies this paper at https://doi.org/10.1186/s12981-020-00272-5.

**Acknowledgements**

We thank the patients and staff in the NCID Clinical HIV Programme who made this study possible.

**Authors’ contributions**

All authors contributed toward the conception of the study and review and revision of the manuscript. SH, JGW, OTN and WCS contributed to data analysis. SH, JGW and WCS drafted the manuscript. WCS served as the senior author, providing technical oversight of data analysis, interpretation and manuscript writing. All authors read and approved the final manuscript.

**Funding**

Not applicable.

**Availability of data and materials**

All data generated or analysed during this study are included in this published article.

**Ethics approval and consent to participate**

Ethics approval for use of the clinical data was obtained from the Singapore National Healthcare Group Domain Specific Review Board (NHG DSRB reference number 2012/00438).

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Author details**

1. Tan Tock Seng Hospital, Singapore, Singapore. 2. Office of Clinical Epidemiology, Analytics and Knowledge, Tan Tock Seng Hospital, Singapore, Singapore. 3. National Centre for Infectious Diseases, Singapore, Singapore. 4. Department of Infectious Diseases, Tan Tock Seng Hospital, Singapore, Singapore. 5. Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore. 6. Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. 7. Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore.

Received: 22 January 2020 Accepted: 4 May 2020

Published online: 21 May 2020

**References**

1. World Health Organisation. Policy brief update of recommendations on first- and second-line antiretroviral regimens, 2019. https://apps.who.int/iris/bitstream/handle/10665/325892/WHO-CDS-HIV-19.15-eng.pdf. Accessed Apr 2020.

2. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. Department of Health and Human Services USA; 2019. https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. Accessed Apr 2020.

3. European AIDS Clinical Society Guidelines Version 10.0, November 2019, initial combination regimen for art-naïve adult people living with HIV. https://www.eacsociety.org/files/2019_guidelines-10.0_final.pdf. Accessed Apr 2020.

4. Gupta RK, Gregson J, Parkin N, Haie-Selassie H, Tanuri A, Andrade Forero L, et al. HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis. Lancet Infect Dis. 2018;18(3):346–55.

5. Mocroft A, Kirk O, Reiss P, De Wit S, Sedlacek D, Beniowski M, et al. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS. 2010;24:1667–78.

6. Negredo E, Diez-Pérez A, Bonjoch A, Domingo P, Pérez-Álvarez N, Gutierrez M, et al. Switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: changes in bone turnover markers and circulating sclerostin levels. J Antimicrob Chemother. 2015;70:2104–7.
7. Imaz A, Podzamczer D. The role of rilpivirine in clinical practice: strengths and weaknesses of the new nonnucleoside reverse transcriptase inhibitor for HIV therapy. AIDS Rev. 2012;14(4):268–78.
8. Taramasso L, Tatarelli P, Ricci E, Madeddu G, Menzaghi B, Squillace N, et al. Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA). BMC Infect Dis. 2018;18(1):357.
9. Molina JM, Cahn P, Grinsztejn B, Lazzarin A, Mills A, Saag M, et al. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naïve adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet. 2011;378:238–46.
10. Cohen CJ, Andrade-Villanueva J, Clotet B, Fourie J, Johnson MA, Ruxrungtham K, et al. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naïve adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet. 2011;378:229–37.
11. Nelson MR, Elion RA, Cohen CJ, Mills A, Hodder SL, Segal-Maurer S, et al. Rilpivirine versus efavirenz in HIV-1-infected subjects receiving emtricitabine/tenofovir DF: pooled 96-week data from ECHO and THRIVE studies. HIV Clin Trials. 2013;14(Suppl 3):S81–91.
12. Curtani A, Rojas J, Cabelló A, Troya J, Imaz A, Domingo P, et al. Effectiveness and safety of an abacavir/lamivudine + rilpivirine regimen for the treatment of HIV-1 infection in naïve patients. J Antimicrob Chemother. 2016;71(12):3510–4.
13. Stanford University HIV Drug Resistance Database. https://hivdb.stanford.edu/dr-summary/resistance-notes/NNRTI/. Accessed Dec 2019.
14. Ford N, Shubber Z, Pozniak A, Vitoria M, Doherty M, Kirby C, et al. Comparative safety and neuropsychiatric adverse events associated with efavirenz use in first-line antiretroviral therapy: a systematic review and meta-analysis of randomized trials. J Acquir Immune Defic Syndr. 2015;69(4):422–9.
15. van Lunzen J, Antinori A, Cohen CJ, Arribas JR, Wohl DA, Rieger A, et al. Rilpivirine vs efavirenz-based single-tablet regimens in treatment-naïve adults: week 96 efficacy and safety from a randomized phase 3b study. AIDS. 2016;30(2):251–9.
16. Edurant Prescribing Information. http://www.edurant.com/hcp/prescribing-information. Accessed Dec 2019.
17. Eaton EF, Tamhane A, Saag M, Mugavero MJ, Kilgore ML. Cost considerations in the current antiretroviral era. AIDS. 2016;30(14):2115–9.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.